Associated Papers
SEAP-GETNE consensus on prognostic and predictive molecular biomarkers in thyroid cancer.
Ruz-Caracuel I et al.
Revista Espanola De Patologia : Publicacion Oficial De La Sociedad Espanola De Anatomia Patologica Y De La Sociedad Espanola De Citologia, 2026
Molecular pathogenesis and therapeutic advances in RET fusion-positive papillary thyroid carcinoma.
Wei Y et al.
Pathology, Research and Practice, 2026
Design, synthesis, and activity evaluation of RET protein degradation based on PROTAC and HyTTD techniques.
Xu N et al.
Bioorganic & Medicinal Chemistry Letters, 2026
Design, Synthesis, and Biological Evaluation of the First Novel Macrocycle-Based FGFR Inhibitors That Overcome Clinically Acquired Resistance.
Xiang S et al.
Journal of Medicinal Chemistry, 2026
RET Gene Alterations in Clinical Practice: A Comprehensive Review and Database Update.
Ricciardi Tenore C et al.
Genes, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Four decades of the RET gene: From discovery to tumor-agnostic therapy.
Takahashi M
Journal of the Formosan Medical Association = Taiwan Yi Zhi, 2025
BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study.
Schöffski P et al.
Esmo Open, 2025
Discovery of APS03118, a Potent and Selective Next-Generation RET Inhibitor with a Novel Kinase Hinge Scaffold.
Zhong J et al.
Journal of Medicinal Chemistry, 2025
Identification of alkynyl nicotinamide HSN748 as a RET solvent-front mutant inhibitor with intracranial efficacy.
Khatri U et al.
Rsc Medicinal Chemistry, 2025
Discovery of an orally bioavailable, CNS active pan-mutant RET kinase heterobifunctional degrader.
Orsi DL et al.
Rsc Medicinal Chemistry, 2025
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present).
Armstrong D et al.
Expert Opinion on Therapeutic Patents, 2025
Design and Discovery of Novel Selective RET Inhibitors with High Central Nervous System Penetration, Enhanced Pharmacokinetics, and Pharmacodynamics.
Wang X et al.
Journal of Medicinal Chemistry, 2025
Frequency of targetable genetic alterations in resectable lung adenocarcinoma: Results from the LORD project.
Bossé Y et al.
Lung Cancer (amsterdam, Netherlands), 2025
YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers.
Katayama Y et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Design, synthesis and evaluation of (E)-1-(4-(2-(1H-pyrazol-5-yl)vinyl)phenyl) derivatives as next generation selective RET inhibitors overcoming RET solvent front mutations (G810C/R).
Xu M et al.
European Journal of Medicinal Chemistry, 2025
Treatment of non-small cell lung cancer with RET rearrangements.
Hoe HJ et al.
Cancer, 2025
Discovery of a Selective and Orally Bioavailable RET Degrader with Effectiveness in Various Mutations.
Hualong M et al.
Journal of Medicinal Chemistry, 2025
Mechanisms of resistance to RET-directed therapies.
Clifton-Bligh RJ
Endocrine-related Cancer, 2025
Rearranged during transfection (RET) lung cancer - Update on targeted therapies.
Mullally WJ et al.
Lung Cancer (amsterdam, Netherlands), 2025
Discovery of an Efficacious RET PROTAC Degrader with Enhanced Antiproliferative Activity against Resistant Cancer Cells Harboring RET Solvent-Front Mutations.
Zhang Q et al.
Journal of Medicinal Chemistry, 2025
Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma.
Hamidi S et al.
Thyroid : Official Journal of the American Thyroid Association, 2025
Structure-Based Design of 2-Aminopyrazolpyrimidopyridone Derivatives as New Rearranged During Transfection (RET) Kinase Inhibitors.
Shen J et al.
Chemical Biology & Drug Design, 2025
Overview of management and therapeutic advances in medullary thyroid cancer.
Jara MA et al.
Endocrine Oncology (bristol, England), 2025
First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors.
Li W et al.
Signal Transduction and Targeted Therapy, 2024
MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer.
Wei X et al.
Cancer Letters, 2024
Primary resistance to selpercatinib in a patient with advanced medullary thyroid cancer.
Pitoia F et al.
Endocrine, 2024
Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.
Zhang Y et al.
Cell Communication and Signaling : Ccs, 2024
Side Chain Investigation of Imidazopyridazine as a Hinge Binder for Targeting Actionable Mutations of RET Kinase.
Maturi A et al.
Acs Medicinal Chemistry Letters, 2024
RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future.
Chen MF et al.
Drugs, 2024
Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: "Shadows and Fogs".
Spitaleri G et al.
Cancers, 2024
Medullary Thyroid Cancer: Molecular Drivers and Immune Cellular Milieu of the Tumour Microenvironment-Implications for Systemic Treatment.
Papachristos AJ et al.
Cancers, 2024
Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.
Wang ZX et al.
Journal of Medicinal Chemistry, 2024
Characterization of the Thyroid Cancer Genomic Landscape by Plasma-Based Circulating Tumor DNA Next-Generation Sequencing.
Tarasova VD et al.
Thyroid : Official Journal of the American Thyroid Association, 2024
The Evolving Treatment Landscape of Medullary Thyroid Cancer.
Laganà M et al.
Current Treatment Options in Oncology, 2023
Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET.
Sahakian N et al.
Cancers, 2023
Medullary Thyroid Cancer: Updates and Challenges.
Gild ML et al.
Endocrine Reviews, 2023
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Miyazaki I et al.
Nature Cancer, 2023
Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors.
Khatri U et al.
Molecular Cancer Therapeutics, 2023
Discovery of 3,5-diaryl-1H-pyrazol-based ureas as potent RET inhibitors.
Wu K et al.
European Journal of Medicinal Chemistry, 2023
Progress and challenges in RET-targeted cancer therapy.
Hu X et al.
Frontiers of Medicine, 2023
RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives.
Addeo A et al.
Pharmacology & Therapeutics, 2023
Medullary thyroid cancer - An update.
Fugazzola L
Best Practice & Research. Clinical Endocrinology & Metabolism, 2023
A Case Report of Poor Response to Selpercatinib in the Presence of a 632_633 RET Deletion.
Wijewardene A et al.
Thyroid : Official Journal of the American Thyroid Association, 2023